In a weight loss market dominated by GLP-1 drugs, AllurionALUR

is floating a buoyant idea. After announcing plans to address common muscle loss while taking weight loss treatments, the gastric balloon maker’s stock skyrocketed nearly 400% in premarket trading Friday. But, as Goldman SachsGS

forecasts a $100B sector by 2030, executive decisions sent the stock plunging.

• While 40% of GLP-1 weight loss stems from withering muscle mass, Allurion’s patients gained 5.6% lean mass while losing 14% of total body weight — via the “world’s first, and only swallowable, procedure-less gastric balloon for weight loss.”
• Allurion’s announcement to study combining therapies catalyzed its stock surge — aiming to become “the gold standard for obesity care” by addressing GLP-1’s muscle-wasting effects.

Bursting the balloon: While Allurion’s stock initially soared on its innovative two-pronged strategy, the $17M company’s announcement to raise $7.4M through selling more shares quickly deflated investor enthusiasm. Announced at peak prices, the dilutive nature of the offering, including warrants for an additional 1.24M shares, sent shares tumbling ~60% from their Friday high — showing that even gastric balloon makers can get too inflated with their timing.